InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: davidal66 post# 796

Thursday, 04/06/2017 9:36:36 PM

Thursday, April 06, 2017 9:36:36 PM

Post# of 2099
I listened to the KOL. Definitely very interesting. MOSPD2 is a new target. In the summary he said, "VBL is developing mAbs and CAR-T for targeting of MOSPD2-positive cancer cells."

MOSPD2 expressed on cell surface of monocytes ... and abundantly in many solid tumors. Not expressed in other cells in the body - only monocytes. Correlates with signaling in monocyte cells. Huge opportunity to block the migration of monocytes.

I think they're on to something ... interesting indeed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News